Equities
  • Price (CHF)438.17
  • Today's Change-6.20 / -1.40%
  • Shares traded2.00
  • 1 Year change-16.38%
  • Beta0.9606
Data delayed at least 15 minutes, as of Feb 05 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Thermo Fisher Scientific Inc. is engaged in accelerating life sciences research, solving complex analytical challenges, increasing laboratory productivity, and improving patient health through diagnostics and the development and manufacture of life-changing therapies. Through its Life Sciences Solutions segment, it provides a portfolio of reagents, instruments and consumables used in biological and medical research, the discovery and production of new drugs and vaccines as well as diagnosis of infection and disease. Through its Analytical Instruments segment, it provides instruments and the supporting consumables, software and services that are used for a range of applications. Its Specialty Diagnostics segment offers a range of diagnostic test kits, reagents, culture media, instruments and associated products. Its Laboratory Products and Biopharma Services segment offers virtually everything needed for the laboratory. It also provides purification and filtration technologies.

  • Revenue in USD (TTM)44.56bn
  • Net income in USD6.70bn
  • Incorporated1960
  • Employees125.00k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
TMO:NYQ since
announced
Transaction
value
Clario IncAnnounced29 Oct 202529 Oct 2025Announced-2.65%9.40bn
Sanofi SA-Steriles Manufacturing SiteDeal completed16 Jul 202516 Jul 2025Deal completed29.87%--
Solventum Corp-Purification & Filtration BusinessDeal completed25 Feb 202525 Feb 2025Deal completed1.36%4.10bn
Data delayed at least 15 minutes, as of Feb 06 2026 21:00 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.